357285-79-1Relevant academic research and scientific papers
Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1Antagonists
Azuaje, Jhonny,Carbajales, Carlos,Contino, Marialessandra,Crespo, Abel,Loza, Maria Isabel,Majellaro, Maria,Sotelo, Eddy,Stefanachi, Angela,Val, Cristina,Brea, José M.,Díaz-Holguín, Alejandro,Estévez, Juan C.,García-Mera, Xerardo,Gioé-Gallo, Claudia,Gutiérrez-De-Terán, Hugo,Prieto-Díaz, Rubén,Rodríguez-García, Carlos
, (2022/01/31)
We herein document a large collection of 108 2-amino-4,6-disubstituted-pyrimidine derivatives as potent, structurally simple, and highly selective A1AR ligands. The most attractive ligands were confirmed as antagonists of the canonical cyclic adenosine monophosphate pathway, and some pharmacokinetic parameters were preliminarilly evaluated. The library, built through a reliable and efficient three-component reaction, comprehensively explored the chemical space allowing the identification of the most prominent features of the structure-activity and structure-selectivity relationships around this scaffold. These included the influence on the selectivity profile of the aromatic residues at positions R4 and R6 of the pyrimidine core but most importantly the prominent role to the unprecedented A1AR selectivity profile exerted by the methyl group introduced at the exocyclic amino group. The structure-activity relationship trends on both A1 and A2AARs were conveniently interpreted with rigorous free energy perturbation simulations, which started from the receptor-driven docking model that guided the design of these series.
COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING THE SAME
-
, (2021/02/04)
The present specification relates to a compound represented by chemical formula 1 and an organic light emitting device comprising the same.
HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME
-
, (2017/10/24)
The present specification provides a heterocyclic compound, and an organic light emitting device including the same. The compound is represented by chemical formula 1. In the chemical formula 1, at least one of X_1 to X_3 is CR_1, and the remainder is N. When at least two R_1s are present, the R_1s are the same or different from each other, and X_1 to X_3 are not all CR_1. At least one of R_1s is an electron withdrawing substituent containing a hetero atom, and the remainder is hydrogen or deuterium. Ar_1 and Ar_2 are the same or different from each other, and are independently a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group. L is a single bond, a substituted or unsubstituted arylene group, or a substituted or unsubstituted heteroarylene group. Ar_3 is a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group.COPYRIGHT KIPO 2017
MULTICYCLIC COMPOUND INCLUDING NITROGEN AND ORGANIC LIGHT EMITTING DEVICE USING THE SAME
-
, (2017/04/19)
Provided are a polycyclic compound including nitrogen, represented by chemical formula 1 and an organic light emitting device using the same. According to an embodiment of the present invention, the compound can improve efficiency of an organic light emit
Three-component assembly of structurally diverse 2-aminopyrimidine-5- carbonitriles
Val, Cristina,Crespo, Abel,Yaziji, Vicente,Coelho, Alberto,Azuaje, Jhonny,El Maatougui, Abdelaziz,Carbajales, Carlos,Sotelo, Eddy
, p. 370 - 378 (2013/07/26)
An expedient route for the synthesis of libraries of diversely decorated 2-aminopyrimidine-5-carbonitriles is reported. This approach is based on a three-component reaction followed by spontaneous aromatization.
A new generation of adenosine receptor antagonists: From di- to trisubstituted aminopyrimidines
van Veldhoven, Jacobus P.D.,Chang, Lisa C.W.,von Frijtag Drabbe Kuenzel, Jacobien K.,Mulder-Krieger, Thea,Struensee-Link, Regina,Beukers, Margot W.,Brussee, Johannes,IJzerman, Adriaan P.
, p. 2741 - 2752 (2008/09/20)
New adenosine receptor ligands were designed as hybrid structures between previously synthesized substituted dicyanopyridines and aminopyrimidines, yielding two series of cyano-substituted diphenylaminopyrimidines. We were interested in assessing the effect of this substitution pattern on both affinity and intrinsic activity, as the dicyanopyridines comprised both agonists and inverse agonists, whereas the original aminopyrimidines were exclusively inverse agonists. It was found that the new compounds were generally selective for adenosine A1 receptors, although affinity for the adenosine A2A receptor was also noticed for some of the compounds. In a cAMP second messenger assay the compounds behaved as inverse agonists rather than agonists. Among the more A1 receptor-selective compounds were 5 (LUF6048), 27 (LUF6040) and 53 (LUF6056) with Ki values of 8.1, 1.2 and 5.7 nM, respectively.
Adenosine receptor ligands and their use in the treatment of disease
-
, (2008/06/13)
The invention relates to cyclic heteroaromatic compounds, containing at least one nitrogen atom, and to their use in the manufacture of medicaments for the treatment of diseases, related to adenosine receptor modulators, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure, substance abuse, sedation and they may be active as muscle relaxants, antipsychotics, anti epileptics, anticonvulsants and cardiaprotective agents.
